Scientists Finally Solve Rare COVID Vaccine Blood Clot Mystery

For years, a rare but deadly side effect shadowed the global rollout of specific COVID-19 vaccines. Now, an international team of researchers has identified the exact mechanism behind the condition, termed vaccine-induced immune thrombocytopenia and thrombosis (VITT), paving the way for safer immunizations in the future.

The investigation focused on adenovirus-vector vaccines, specifically those developed by Oxford-AstraZeneca and Johnson & Johnson. While these vaccines saved millions of lives, they were linked to rare cases of dangerous clotting and low platelet counts in approximately one in 200,000 recipients.

According to a study published in the New England Journal of Medicine, the culprit is a case of mistaken identity known as "molecular mimicry".

The researchers discovered that a protein used in the adenovirus vector (protein VII) bears a striking structural resemblance to a human blood protein called Platelet Factor 4 (PF4). In patients with a specific genetic predisposition, the immune system confuses the two. This triggers the production of "rogue" antibodies that lock onto the human PF4 protein instead of the virus, activating platelets and causing catastrophic clots.

"It is a brilliant piece of molecular sleuthing," said Dr. James McCluskey of the University of Melbourne, noting that the study unravels how a normal immune response can turn into pathogenic autoimmunity.

The team used advanced mass spectrometry to pinpoint a specific mutation in the antibody-producing B cells of affected patients. This mutation changes the electrical charge of the antibody, allowing it to bind magnetically to human blood proteins. This explains why the reaction was so rare: it requires both a specific inherited gene variant—found in up to 60% of people of European ancestry—and an accidental, "unlucky" mutation during the immune response.

The implications of this finding extend beyond COVID-19. Adenovirus vectors are currently used in vaccines for Ebola and are being tested for malaria and tuberculosis.

"By modifying or removing this specific adenovirus protein, future vaccines can avoid this extremely rare reaction while continuing to provide strong protection against disease," said lead author Jing Jing Wang. Experts believe this roadmap will allow scientists to redesign adenovirus vectors, preserving a vital, low-cost technology for global health while eliminating the risk of VITT.

---

🔖 Sources

Scientists Finally Solve the Mystery Behind Rare COVID Vaccine Blood Clots

Researchers pinpoint cause of rare but life-threatening blood clots after adenovirus-based COVID vaccination

Rare, dangerous side effects of some COVID-19 vaccines explained

---

Keywords: COVID Vaccine Blood Clot Mystery

COVID Vaccine Blood Clot Mystery

---